Cases of acute myeloid leukemia (AML) are increasing around the world, according to a new study.
The results of the study published in the Journal of the National Comprehensive Cancer Network revealed AML cases increased by 34.6% in men and 7.9% in women between 1990 and 2019, the company TC BioPharm said in a news release.
"The global increase of AML cases marks an urgent need for the health care industry to invest in the most promising therapeutics to combat this cancer. This message is further amplified by orphan disease designation by regulatory agencies," Bryan Kobel, CEO of TC BioPharm, said in the release.
The company's drug, OmnImmune, is currently in clinical trials, the news release said.
"The lack of a toxicity in our OmnImmune trials points to potential value in AML as a stand-alone therapeutic and also as a potential combination therapy to help patients with no existing treatment options," Kobel said. "We hope to bring the product to market in 2023 with our Orphan drug status granted and look forward to making significant impact in the lives of AML patients and the treatment of this devastating disease."
TC BioPharm, based in the United Kingdom, "manufactures young, active gamma-delta T cells" and infuses the healthy donor cells into cancer patients, the news release said.